← Leaderboards
Mario Luis Santiago
University Of Colorado Denver
$9,294,870
Attributed
$12,231,966
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,231,966 · 8
By mechanism
R01$10,251,067 · 4
R56$1,148,361 · 2
R21$832,538 · 2
Top collaborators
- Cara C Wilson13 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Cara C Wilson$18,310,415
- Adam Zweifach$3,368,995
- Hong Li$1,678,312
- Judith T Blaine$5,081,736
- Russell V Anthony$3,363,458
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesInsightMediatingLinkHiv-1BiologyInfectionIn VivoReportingCd4 Positive T LymphocytesResponseImmuneCellsPathogenesisPropertyT-Cell DepletionCytokineSignal TransductionViralAutomobile DrivingGastrointestinal Tract StructureAcutePhenotypeLamina Propria
Grant awards (25)
The Public Mucosal Antibody Repertoire in HIV-1 Infection$195,000
R21 · FY2025 · AI · contact PI
Gut Cytotoxic CD4 T cells in HIV-1 Pathogenesis$445,694
R01 · FY2024 · AI
The Public Mucosal Antibody Repertoire in HIV-1 Infection$210,600
R21 · FY2024 · AI · contact PI
Gut Cytotoxic CD4 T cells in HIV-1 Pathogenesis$445,694
R01 · FY2023 · AI
Gut Cytotoxic CD4 T cells in HIV-1 Pathogenesis$445,694
R01 · FY2022 · AI
Role of Type I IFNs in Mucosal HIV-1 Immunity and Pathogenesis$549,857
R01 · FY2021 · AI · contact PI
Gut Cytotoxic CD4 T cells in HIV-1 Pathogenesis$445,694
R01 · FY2021 · AI
Role of Type I IFNs in Mucosal HIV-1 Immunity and Pathogenesis$549,857
R01 · FY2020 · AI · contact PI
APOBEC3/Rfv3 and Immunoglobulin Somatic Hypermutation$493,499
R01 · FY2020 · AI · contact PI
Gut Cytotoxic CD4 T cells in HIV-1 Pathogenesis$445,694
R01 · FY2020 · AI
Role of Type I IFNs in Mucosal HIV-1 Immunity and Pathogenesis$549,857
R01 · FY2019 · AI · contact PI
APOBEC3/Rfv3 and Immunoglobulin Somatic Hypermutation$493,499
R01 · FY2019 · AI · contact PI
Role of Type I IFNs in Mucosal HIV-1 Immunity and Pathogenesis$549,857
R01 · FY2018 · AI · contact PI
APOBEC3/Rfv3 and Immunoglobulin Somatic Hypermutation$493,499
R01 · FY2018 · AI · contact PI
Role of Type I IFNs in Mucosal HIV-1 Immunity and Pathogenesis$549,857
R01 · FY2017 · AI · contact PI
APOBEC3/Rfv3 and Immunoglobulin Somatic Hypermutation$493,499
R01 · FY2017 · AI · contact PI
APOBEC3/Rfv3 and Immunoglobulin Somatic Hypermutation$493,499
R01 · FY2016 · AI · contact PI
HIV-Associated Interferon Effector Mechanisms in the GALT$490,838
R56 · FY2015 · AI · contact PI
Immunological impact of Tetherin retrovirus restriction$194,375
R21 · FY2015 · AI · contact PI
Immunological impact of Tetherin retrovirus restriction$232,563
R21 · FY2014 · AI · contact PI
Innate Restriction Factor Modulation of Retrovirus-specific Humoral Immunity$644,945
R01 · FY2013 · AI · contact PI
Innate Restriction Factor Modulation of Retrovirus-specific Humoral Immunity$698,338
R01 · FY2012 · AI · contact PI
Innate Restriction Factor Modulation of Retrovirus-specific Humoral Immunity$709,630
R01 · FY2011 · AI · contact PI
Innate Restriction Factor Modulation of Retrovirus-specific Humoral Immunity$752,904
R01 · FY2010 · AI · contact PI
Apobec3 and the Neutralizing Antibody Response Against Pathogenic Retroviruses$657,523
R56 · FY2009 · AI · contact PI